Sibel Ata
Research Subjects
Sibel Ata has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Hatice Kayış Topaloğlu
NOVEL Health Strategies, Chevy Chase, MD, USA
2 shared publications - Melih Kızıltepe
Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Erciyes University, Kayseri, Turkey
2 shared publications - Mesut Kılıç
Department of Internal Medicine , Kayseri City Hospital , Kayseri , Turkey
2 shared publications - Sami Bahçebaşı
Internal Medicine Department, Kayseri City Hospital, Kayseri, Turkey
2 shared publications - Ulaş Serkan Topaloğlu
Department of Internal Medicine, Kayseri City Hospital, 38080 Kayseri, Türkiye
2 shared publications - Yasin Şimşek
Department of Endocrinology , Kayseri City Hospital , Kayseri , Turkey
2 shared publications
Latest Publications
- Open Access
- 23 December 2020
- Published by Walter de Gruyter GmbH in Drug Metabolism and Drug Interactions
- Vol. 36 (2) , 129-134
Fear of Hypoglycemia in Adults with diabetes mellitus switching to Treatment with IDegAsp Co-formulation to Examine real-world setting: an observational study (The HATICE study)
Objectives: To evaluate the clinical results of insulin degludec/aspart (IDEgAsp) therapy and its effect on the fear of hypoglycemia. Methods: A prospective observational study has been conducted through surveys of 36 patients using insulin because of type 2 diabetes mellitus who initiated treatment with IDegAsp switching from other insulins. Patients, 18–75 years old, were recruited to the study, consecutively. Participants’ age, gender, height, weight, body mass index (BMI), daily insulin dose, glycated hemoglobin (HbA1c), hypoglycemia rate, hypoglycemia fear survey (HFS) were recorded at the beginning of the study. By the end of 12th month, data was re-measured and compared with each other. Results: HbA1c was declined by mean of −1.59% (95% CI −1.06 to −2.12, p1c, less injection administration, and decreased the fear of hypoglycemia in diabetics.
- 23 December 2020
- Published by Walter de Gruyter GmbH in Drug Metabolism and Drug Interactions
- Vol. 36 (2) , 129-134
Open AccessFear of Hypoglycemia in Adults with diabetes mellitus switching to Treatment with IDegAsp Co-formulation to Examine real-world setting: an observational study (The HATICE study)
Objectives: To evaluate the clinical results of insulin degludec/aspart (IDEgAsp) therapy and its effect on the fear of hypoglycemia. Methods: A prospective observational study has been conducted through surveys of 36 patients using insulin because of type 2 diabetes mellitus who initiated treatment with IDegAsp switching from other insulins. Patients, 18–75 years old, were recruited to the study, consecutively. Participants’ age, gender, height, weight, body mass index (BMI), daily insulin dose, glycated hemoglobin (HbA1c), hypoglycemia rate, hypoglycemia fear survey (HFS) were recorded at the beginning of the study. By the end of 12th month, data was re-measured and compared with each other. Results: HbA1c was declined by mean of −1.59% (95% CI −1.06 to −2.12, p1c, less injection administration, and decreased the fear of hypoglycemia in diabetics.
- Open Access
- 21 October 2020
- Published by Walter de Gruyter GmbH in Drug Metabolism and Personalized Therapy
- Vol. -1 (ahead-of-p)
Fear of hypoglycemia in adults with diabetes mellitus switching to treatment with IDegAsp co-formulation to examine real-world setting: an observational study (The HATICE study)
Objectives: To evaluate the clinical results of insulin degludec/aspart (IDEgAsp) therapy and its effect on the fear of hypoglycemia. Methods: A prospective observational study has been conducted through surveys of 36 patients using insulin because of type 2 diabetes mellitus who initiated treatment with IDegAsp switching from other insulins. Patients, 18–75 years old, were recruited to the study, consecutively. Participants’ age, gender, height, weight, body mass index (BMI), daily insulin dose, glycated hemoglobin (HbA1c), hypoglycemia rate, hypoglycemia fear survey (HFS) were recorded at the beginning of the study. By the end of 12th month, data was re-measured and compared with each other. Results: HbA1c was declined by mean of −1.59% (95% CI −1.06 to −2.12, p1c, less injection administration, and decreased the fear of hypoglycemia in diabetics.
- 21 October 2020
- Published by Walter de Gruyter GmbH in Drug Metabolism and Personalized Therapy
- Vol. -1 (ahead-of-p)
Open AccessFear of hypoglycemia in adults with diabetes mellitus switching to treatment with IDegAsp co-formulation to examine real-world setting: an observational study (The HATICE study)
Objectives: To evaluate the clinical results of insulin degludec/aspart (IDEgAsp) therapy and its effect on the fear of hypoglycemia. Methods: A prospective observational study has been conducted through surveys of 36 patients using insulin because of type 2 diabetes mellitus who initiated treatment with IDegAsp switching from other insulins. Patients, 18–75 years old, were recruited to the study, consecutively. Participants’ age, gender, height, weight, body mass index (BMI), daily insulin dose, glycated hemoglobin (HbA1c), hypoglycemia rate, hypoglycemia fear survey (HFS) were recorded at the beginning of the study. By the end of 12th month, data was re-measured and compared with each other. Results: HbA1c was declined by mean of −1.59% (95% CI −1.06 to −2.12, p1c, less injection administration, and decreased the fear of hypoglycemia in diabetics.